[From the "note limitative" to the "registri AIFA"].

Area of Science:

• Health Services Research
• Pharmacovigilance
• Health Policy

Background:

• Over the last decade, Italy has seen a significant increase in drug reimbursement registers.
• These registers emerged from regulatory directives like "note limitative" and specific drug treatment plans.
• This regulatory environment supports the use of medications with not-yet-well-defined benefit-risk profiles.

Purpose of the Study:

• To critically analyze the development and implementation of drug reimbursement registers in Italy.
• To evaluate the positive and negative aspects of these registries in clinical practice.
• To understand the impact of these registries on drug safety and appropriateness monitoring.

Main Methods:

• Review of regulatory frameworks driving the creation of drug registers.
• Analysis of data collection practices within selected Italian drug reimbursement registries.
• Qualitative assessment of the experiences associated with these registries.

Main Results:

• Registers collect essential data on drug safety and appropriateness at the point of prescription.
• Experiences with these registries highlight both benefits and drawbacks in national clinical practice.
• The proliferation of registers is directly linked to specific reimbursement and treatment plan regulations.

Conclusions:

• Drug reimbursement registers are an established regulatory reality in Italian clinical practice.
• Critical analysis reveals a complex landscape of advantages and disadvantages associated with these registries.
• Further evaluation is needed to optimize the role of registries in ensuring safe and appropriate medication use.